Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GILEAD SCIENCES : DZ Bank reaffirms its Buy rating

share with twitter share with LinkedIn share with facebook
06/15/2020 | 08:24am EDT

Elmar Kraus from DZ Bank retains his positive opinion on the stock with a Buy rating.

© MarketScreener with dpa-AFX Analyser 2020

share with twitter share with LinkedIn share with facebook
All news about GILEAD SCIENCES, INC.
10:22aGILEAD SCIENCES : European CHMP Adopts Positive Opinion for Kite's KTE-X19 for t..
AQ
08:33aGILEAD SCIENCES : Presents New Data from Antiviral Development Programs at IDWee..
BU
10/16GILEAD SCIENCES : WHO-Backed Study Finds No Remdesivir Benefit for Hospitalized ..
DJ
10/16GILEAD SCIENCES : FDA Says Remdesivir EUA Letter Of Authorization, Reissued Oct ..
RE
10/16GILEAD SCIENCES : Statement on the Solidarity Trial
PU
10/16GILEAD SCIENCES : WHO-Backed Study Finds No Remdesivir Benefit for Hospitalized ..
DJ
10/16GILEAD SCIENCES : EU urged to review remdesivir supply deal after COVID-19 trial..
RE
10/16GLOBAL MARKETS LIVE : Gilead, Daimler, Pfizer…
10/16GILEAD SCIENCES : Kite Says CHMP Adopts Positive Opinion for Lymphoma Drug
DJ
10/16GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Kite's KTE-X19 for t..
BU
More news
Financials (USD)
Sales 2020 24 074 M - -
Net income 2020 2 180 M - -
Net Debt 2020 3 105 M - -
P/E ratio 2020 38,5x
Yield 2020 4,33%
Capitalization 77 731 M 77 731 M -
EV / Sales 2020 3,36x
EV / Sales 2021 3,36x
Nbr of Employees 11 800
Free-Float 99,6%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 78,29 $
Last Close Price 62,00 $
Spread / Highest target 69,4%
Spread / Average Target 26,3%
Spread / Lowest Target -8,06%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-4.59%77 731
REGENERON PHARMACEUTICALS59.73%63 111
VERTEX PHARMACEUTICALS-0.40%56 803
WUXI APPTEC CO., LTD.60.41%39 207
BEIGENE, LTD.91.01%28 693
GENMAB A/S58.42%24 152